Total Funding
62
57
Total FundingSeries A raised
Growth Score 62 in past quarter
-2 pts
Heat Score 57 in past quarter
-6 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
40737
Nitrase Therapeutics is developing drugs against newly discovered nitration enzyme(s).
- Irene Griswold-Prenner: Founder & CSOPast Role: iPierian, Senior Director of Cell Biology
- Pierre Beaurang: Chief Executive OfficerPast Role: DeCART Therapeutics, Co-Founder
About the Company
Nitrase Therapeutics is a platform company developing drugs against a newly identified class of enzymes called Nitrases, initially targeting Parkinson’s disease. The therapies that Nitrome is developing will target these enzymes and potentially help slow or halt the progression of diseases such as Parkinson’s. While the initial focus is on
Parkinson's disease, the company aims to expand its proprietary platform to include other disease indications.
Women Founded